Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort ascending | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Somatuline Autogel | Lanreotide acetate | Acromegaly | List in a similar manner to other drugs in class | Complete | ||
| Onbrez | Indacaterol | Chronic obstructive pulmonary disease | List in a similar manner | Complete | ||
| Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete | ||
| Stalevo | Carbidopa, levodopa and entacapone | Parkinsons Disease | List in a similar manner | Complete | ||
| Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Orencia | Abatacept | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Blepharospasm | List in a similar manner | Complete | ||
| Xeomin | Clostridium botulinum neurotoxin type A, free from complexing proteins | Cervical Dystonia | List in a similar manner | Complete | ||
| Simponi | Golimumab | Arthritis, psoriatic | List in a similar manner | Complete | ||
| Simponi | Golimumab | Ankylosing spondylitis | List in a similar manner | Complete |
Last Updated : May 14, 2024